Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
PRODUCTS
About Autoimmune Disease
Autoimmune disease is an abnormal reaction of the bodys immune system toward its own tissues and organs. The normal functions of the immune cells (white blood cells), a key component of the immune system, are to help protect against bacteria, viruses, toxins, and cancer. In autoimmune diseases, however, the immune system fails to distinguish between self tissues and foreign pathogens. As a result, the body sets off an overreaction that attacks and destroys otherwise healthy tissues. Autoimmune disease can affect many different organs and tissues. The most common autoimmune diseases are rheumatoid arthritis, psoriasis, multiple sclerosis, inflammation bowel disease (IBD), type I diabetes. But there are numerous serious though lesser known diseases that are life threatening and have no effective treatment. At least 80 diseases are believed to be caused by autoimmunity.
 
CBP-307 for autoimmune diseases
CBP-307 is a small molecule modulator of a G-protein coupled receptor called S1P1, known to be critical for T cell trafficking in the body. This drug candidate is designed to avoid the side effects on cardiovascular, lung and liver functions that are known for a marketed, first generation drug targeting the same receptor. Based our preclinical data we believe this compound has the potential to be far superior than the first generation drug, and has advantages over current second generation compounds now in various stages of development. Phase I studies of CBP-307 has been launched in November of 2014 in Australia. Filing with the SFDA is expected in mid 2015.
 
CBP-174 for allergic rhinitis and atopic dermatitis
CBP-174 is a small molecule inhibitor of a G-protein coupled receptor involved in nasal congestion due to allergy and pruritus in chronic skin inflammation. It has a completely different mode of action from the commonly used antihistamines and is designed to offer therapeutic benefits that traditional antihistamines do not provide. The drug candidate is selected from a lead portforlio in-licensed from Arena Pharmaceuticals (NASDAQ:ARNA). Our preclinical studies demonstrated that the compound is high potent and selective, and is highly efficacious in the relevant preclinical models. This compound has the potential to be first-in-class. It is currently in preclinical development.
 
CBP-201 for asthma and atopic dermatitis
CBP-201 is a monoclonal antibody directed against a receptor found on immune cells that are involved in allergic inflammation such as asthma and atopic dermatitis. Extensive preclinical and clinical studies have shown that blocking this receptor offer significant protection from allergic inflammation. CBP-201 is discovered internally and is wholly-own by Suzhou Connect Biopharma, and is currently under preclinical evaluation. This drug candidate has the potential to be best-in-class.
Copyright: Suzhou Connect Biopharmaceuticals, Ltd.